These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38044652)

  • 1. Advances in the pathogenesis of multiple myeloma bone disease.
    Hu C; Kuang C; Zhou W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1403-1410. PubMed ID: 38044652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
    Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloma bone disease: Progress in pathogenesis.
    Xi H; An R; Li L; Wang G; Tao Y; Gao L
    Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
    Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
    Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functional three-dimensional microphysiological human model of myeloma bone disease.
    Visconti RJ; Kolaja K; Cottrell JA
    J Bone Miner Res; 2021 Oct; 36(10):1914-1930. PubMed ID: 34173283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
    Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
    Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone disease in multiple myeloma].
    Irisawa H
    Nihon Rinsho; 2015 Jan; 73(1):42-6. PubMed ID: 25626302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
    Zhou F; Meng S; Song H; Claret FX
    Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.
    Liu Y; Li B; Chen X; Xiong H; Huang C
    Expert Rev Hematol; 2024; 17(1-3):47-54. PubMed ID: 38319240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.